See more : NewLake Capital Partners, Inc. (NLCP) Income Statement Analysis – Financial Results
Complete financial analysis of Cue Biopharma, Inc. (CUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cue Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- XPAC Acquisition Corp. (XPAXW) Income Statement Analysis – Financial Results
- Chongqing Fuling Zhacai Group Co., Ltd. (002507.SZ) Income Statement Analysis – Financial Results
- Macy’s, Inc. (M) Income Statement Analysis – Financial Results
- IonQ, Inc. WT (IONQ-WT) Income Statement Analysis – Financial Results
- Sakthi Sugars Limited (SAKHTISUG.BO) Income Statement Analysis – Financial Results
Cue Biopharma, Inc. (CUE)
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.10M | 1.81M | -1.78M | 33.55M | 27.49M | 28.54M | 419.57K | 202.09K | 44.82K |
| Gross Profit | -32.61M | -560.83K | 16.72M | -30.39M | -24.03M | -27.40M | -419.57K | -202.09K | -44.82K |
| Gross Profit Ratio | -593.93% | -45.04% | 111.90% | -963.48% | -694.90% | -2,398.16% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.80M | 38.58M | 41.35M | 33.55M | 27.49M | 28.54M | 18.90M | 5.69M | 1.50M |
| General & Administrative | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Other Expenses | -37.94M | 0.00 | 0.00 | 0.00 | 64.00K | 165.34K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.54M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Cost & Expenses | 57.64M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Interest Income | 2.66M | 928.24K | 45.90K | 463.91K | 419.00K | 376.01K | 35.00 | 52.00 | 0.00 |
| Interest Expense | 1.25M | 713.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.44M | 1.81M | -1.78M | 1.06M | 5.35M | 760.01K | 419.57K | 202.09K | 44.82K |
| EBITDA | -46.05M | -50.49M | -45.44M | -43.99M | -35.96M | -37.94M | -22.81M | -7.46M | -1.88M |
| EBITDA Ratio | -838.83% | -4,076.94% | -292.56% | -1,394.44% | -1,063.30% | -3,320.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -52.15M | -53.22M | -43.71M | -45.04M | -36.77M | -38.70M | -23.23M | -7.66M | -1.93M |
| Operating Income Ratio | -949.89% | -4,274.31% | -292.56% | -1,427.96% | -1,063.30% | -3,386.71% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 215.00K | 45.90K | 463.91K | 482.79K | 541.35K | 35.00 | 52.00 | 0.00 |
| Income Before Tax | -50.73M | -53.01M | -43.67M | -44.58M | -36.29M | -38.16M | -23.23M | -7.66M | -1.93M |
| Income Before Tax Ratio | -924.10% | -4,257.09% | -292.25% | -1,413.26% | -1,049.33% | -3,339.33% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -214.43K | 495.00K | 206.25K | 412.00K | 825.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -50.73M | -52.80M | -44.16M | -44.78M | -36.70M | -38.98M | -23.23M | -7.66M | -1.93M |
| Net Income Ratio | -924.10% | -4,239.87% | -295.56% | -1,419.79% | -1,061.25% | -3,411.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| EPS Diluted | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| Weighted Avg Shares Out | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
| Weighted Avg Shares Out (Dil) | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
NexImmune Proposes Terms For $75 Million IPO
7 Stocks With Insider Buying This Week Worth A Look
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck
Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates
Cue Biopharma to Present at Upcoming Investor Conferences in November 2020
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports